Circ Cardiovasc Interv

Slides:

Advertisements

Similar presentations

M Gaudino. 2 Loop FD et al NEJM 1986 Arterial conduits used for coronary artery bypass grafting - Internal Thoracic Artery - Radial Artery - Right.

Advertisements

Cumulative Radiation Exposure and Cancer Risk Estimation in Children With Heart DiseaseCLINICAL PERSPECTIVE by Jason N. Johnson, Christoph P. Hornik, Jennifer.

A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous.

(p for noninferiority = 0.01)

Global Experience with Peripheral DCBs/Stent Studies: C.R. Bard

Superficial Femoral Artery Recanalization with Self-expanding Nitinol Stents: Long-term Follow-up Results M. Ferreira, L. Lanziotti, M. Monteiro, G.

Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease Yiu Che Chan, MBBS, MD, FRCS, Stephen.

Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease Yiu Che Chan, MBBS, MD, FRCS, Stephen.

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Three-dimensional Mapping of the Initiation of Nonsustained Ventricular Tachycardia in the Human Heart by Mina K. Chung, Steven M. Pogwizd, Dave P. Miller,

Circ Cardiovasc Interv

Spontaneous Coronary Artery Dissection

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Six-month–adjusted survival after aortic valve replacement (AVR) for severe aortic stenosis (AS) stratified by procedure and preoperative ejection fraction.

Value-Based Hypothesis Testing for Cardiac Device Clinical Trials

Circ Cardiovasc Qual Outcomes

Optima DES system: The stent has multiple grooves (reservoirs) on its abluminal surface into which the drug is loaded. Optima DES system: The stent has.

Association Between Mycoplasma Pneumonia and Increased Risk of Ischemic Stroke by Chia-Hung Chiang, Chin-Chou Huang, Wan-Leong Chan, Yu-Chun Chen, Tzeng-Ji.

Circ Cardiovasc Qual Outcomes

Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.

Physician and Patient Influences on Provider Performance

by Thomas Monks, Martin Pitt, Ken Stein, and Martin James

Circ Cardiovasc Interv

Relative Distributions

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Influence of Cardiac Surgeon Report Cards on Patient Referral by Cardiologists in New York State After 20 Years of Public Reporting by David L. Brown,

Effect of Provider Volume on the Accuracy of Hospital Report Cards

New Frontiers in Cardiology

Circ Cardiovasc Interv

Circ Arrhythm Electrophysiol

Iatrogenic Adverse Events in the Coronary Care Unit

Statin Treatment and Functional Outcome After Ischemic Stroke

Attenuation of Rebound Ischemia After Discontinuation of Heparin Therapy by Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Acute Coronary.

Box plot showing percentage change in early diastolic pulsed-Doppler mitral inflow (E)/early diastolic tissue Doppler velocity (E´) from pre– to post–balloon.

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Mathematical representation of Bayes theorem.

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Qual Outcomes

by Clarisse Toledo, George Thomas, Jesse D

by Kamyar Kalantar-Zadeh, Ryan D. Kilpatrick, Charles J

Using the Coronary Artery Calcium Score to Guide Statin Therapy

Circ Cardiovasc Interv

Cancer in Young Adults With Ischemic Stroke

Circ Cardiovasc Interv

Catheter-Based Treatment of Coronary Artery Disease

Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease Yiu Che Chan, MBBS, MD, FRCS, Stephen.

Primary stenting of femoropopliteal atherosclerotic lesions using new helical interwoven nitinol stents Yiu Che Chan, MBBS, BSc, MD, FRCS, Stephen W.

FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.

Milen Pavlović, Nebojša Jović, Tatjana Pekmezović

Percutaneous transluminal angioplasty for the treatment of limb threatening ischemia: Do the results justify an attempt before bypass grafting? Richard.

One-year outcomes of the U. S

Endovascular aortoiliac grafts in combination with standard infrainguinal arterial bypasses in the management of limb-threatening ischemia: Preliminary.

Local thrombolysis in the treatment of thrombosed arteries, bypass grafts, and arteriovenous fistulas Robert A. Graor, M.D., Barbara Risius, M.D., Kevin.

Volume 89, Issue 5, Pages (May 2016)

The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé.

Primary stenting of the superficial femoral and popliteal artery

Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive.

Kaplan–Meier survival curve for major adverse cardiac events (MACE): a trend towards superior survival in patients without signs of coronary artery disease.

Clinical failure after percutaneous transluminal angioplasty of the superficial femoral and popliteal arteries Laura A. Karch, MD, Mark A. Mattos, MD,

Efficacious use of nitinol stents in the femoral and popliteal arteries Todd R Vogel, MD, Larry E Shindelman, MD, Gary B Nackman, MD, Alan M Graham, MD

Early outcome and intermediate follow-up of vascular stents in the femoral and popliteal arteries without long-term anticoagulation Geoffrey H. White,

Progression and survival analysis.

Presentation transcript:

Circ Cardiovasc Interv Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries by Lawrence Garcia, Michael R. Jaff, Christopher Metzger, Gino Sedillo, Ashish Pershad, Frank Zidar, Raghotham Patlola, Robert G. Wilkins, Andrey Espinoza, Ayman Iskander, George S. Khammar, Yazan Khatib, Robert Beasley, Satyaprakash Makam, Richard Kovach, Suraj Kamat, Luis R. Leon, William Britton Eaves, Jeffrey J. Popma, Laura Mauri, Dennis Donohoe, Carol C. Base, and Kenneth Rosenfield Circ Cardiovasc Interv Volume 8(5):e000937 May 12, 2015 Copyright © American Heart Association, Inc. All rights reserved.

Survival analysis of freedom from loss of patency showing Kaplan–Meier probability estimates. Survival analysis of freedom from loss of patency showing Kaplan–Meier probability estimates. Data for this analysis included the day of event, death, loss to follow-up or withdrawal, whichever came first, or the last day of follow-up in patients who did not incur any of the above. Patients who did not experience an event and for whom the survival time was ≤390 days were censored. Six-month ultrasound-confirmed restenoses are included only if they were also confirmed by ultrasound at 12 months. Lawrence Garcia et al. Circ Cardiovasc Interv. 2015;8:e000937 Copyright © American Heart Association, Inc. All rights reserved.